Cargando…
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
BACKGROUND: The 10-m walk test (10MWT) is a widely used measure of gait speed in Parkinson’s disease (PD). However, it is unclear if different standardizations of its conduct impact test results. AIM OF THE STUDY: We examined the clinical significance of two aspects of the standardization of the 10M...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060742/ https://www.ncbi.nlm.nih.gov/pubmed/29876762 http://dx.doi.org/10.1007/s00415-018-8921-9 |
_version_ | 1783342075673051136 |
---|---|
author | Lindholm, Beata Nilsson, Maria H. Hansson, Oskar Hagell, Peter |
author_facet | Lindholm, Beata Nilsson, Maria H. Hansson, Oskar Hagell, Peter |
author_sort | Lindholm, Beata |
collection | PubMed |
description | BACKGROUND: The 10-m walk test (10MWT) is a widely used measure of gait speed in Parkinson’s disease (PD). However, it is unclear if different standardizations of its conduct impact test results. AIM OF THE STUDY: We examined the clinical significance of two aspects of the standardization of the 10MWT in mild PD: static vs. dynamic start, and a single vs. repeated trials. Implications for fall prediction were also explored. METHODS: 151 people with PD (mean age and PD duration, 68 and 4 years, respectively) completed the 10MWT in comfortable gait speed with static and dynamic start (two trials each), and gait speed (m/s) was recorded. Participants then registered all prospective falls for 6 months. RESULTS: Absolute mean differences between outcomes from the various test conditions ranged between 0.016 and 0.040 m/s (effect sizes, 0.06–0.14) with high levels of agreement (intra-class correlation coefficients, 0.932–0.987) and small standard errors of measurement (0.032–0.076 m/s). Receiver operating characteristic curves showed similar discriminate abilities for prediction of future falls across conditions (areas under curves, 0.70–0.73). Cut-off points were estimated at 1.1–1.2 m/s. CONCLUSIONS: Different 10MWT standardizations yield very similar results, suggesting that there is no practical need for an acceleration distance or repeated trials when conducting this test in mild PD. |
format | Online Article Text |
id | pubmed-6060742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-60607422018-08-09 The clinical significance of 10-m walk test standardizations in Parkinson’s disease Lindholm, Beata Nilsson, Maria H. Hansson, Oskar Hagell, Peter J Neurol Original Communication BACKGROUND: The 10-m walk test (10MWT) is a widely used measure of gait speed in Parkinson’s disease (PD). However, it is unclear if different standardizations of its conduct impact test results. AIM OF THE STUDY: We examined the clinical significance of two aspects of the standardization of the 10MWT in mild PD: static vs. dynamic start, and a single vs. repeated trials. Implications for fall prediction were also explored. METHODS: 151 people with PD (mean age and PD duration, 68 and 4 years, respectively) completed the 10MWT in comfortable gait speed with static and dynamic start (two trials each), and gait speed (m/s) was recorded. Participants then registered all prospective falls for 6 months. RESULTS: Absolute mean differences between outcomes from the various test conditions ranged between 0.016 and 0.040 m/s (effect sizes, 0.06–0.14) with high levels of agreement (intra-class correlation coefficients, 0.932–0.987) and small standard errors of measurement (0.032–0.076 m/s). Receiver operating characteristic curves showed similar discriminate abilities for prediction of future falls across conditions (areas under curves, 0.70–0.73). Cut-off points were estimated at 1.1–1.2 m/s. CONCLUSIONS: Different 10MWT standardizations yield very similar results, suggesting that there is no practical need for an acceleration distance or repeated trials when conducting this test in mild PD. Springer Berlin Heidelberg 2018-06-06 2018 /pmc/articles/PMC6060742/ /pubmed/29876762 http://dx.doi.org/10.1007/s00415-018-8921-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Communication Lindholm, Beata Nilsson, Maria H. Hansson, Oskar Hagell, Peter The clinical significance of 10-m walk test standardizations in Parkinson’s disease |
title | The clinical significance of 10-m walk test standardizations in Parkinson’s disease |
title_full | The clinical significance of 10-m walk test standardizations in Parkinson’s disease |
title_fullStr | The clinical significance of 10-m walk test standardizations in Parkinson’s disease |
title_full_unstemmed | The clinical significance of 10-m walk test standardizations in Parkinson’s disease |
title_short | The clinical significance of 10-m walk test standardizations in Parkinson’s disease |
title_sort | clinical significance of 10-m walk test standardizations in parkinson’s disease |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060742/ https://www.ncbi.nlm.nih.gov/pubmed/29876762 http://dx.doi.org/10.1007/s00415-018-8921-9 |
work_keys_str_mv | AT lindholmbeata theclinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease AT nilssonmariah theclinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease AT hanssonoskar theclinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease AT hagellpeter theclinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease AT lindholmbeata clinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease AT nilssonmariah clinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease AT hanssonoskar clinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease AT hagellpeter clinicalsignificanceof10mwalkteststandardizationsinparkinsonsdisease |